BPC-157 vs TB-500
BPC-157 is a synthetic pentadecapeptide derived from a fragment of a protein found in gastric juice, and its literature is overwhelmingly rodent work on tendon, ligament, muscle and gastrointestinal injury. TB-500 is the synthetic Ac-LKKTETQ fragment marketed as an analogue of thymosin beta-4, a 43-amino-acid endogenous actin-sequestering peptide whose own literature covers wound healing, angiogenesis, cardiac repair and fibrosis. The two are habitually paired because both are promoted for soft-tissue recovery and both are prohibited in sport. Unusually for this category, one direct comparison exists: a 2026 rat Achilles tendon study tested each peptide alone and in combination against an untreated control. That single animal experiment is the entire body of head-to-head evidence, and no human study has compared them.
They have been compared directly.
Biçer and colleagues randomised 32 male Sprague-Dawley rats after standardised Achilles tendon transection and repair into four groups of eight: control, BPC-157, TB-500, and the two peptides combined, with intraperitoneal treatment for four weeks. Both peptide groups showed higher maximum load to failure than controls, but statistical significance was reached only in the TB-500 group, which also showed significantly lower total Bonar and Movin histopathological scores and the most pronounced increase in type I collagen organisation on Sirius red birefringence. The combination group showed significantly lower total Movin scores than controls but conferred no additional benefit over either peptide given alone; the authors suggested convergence on shared downstream pathways as a possible explanation and stated that the hypothesis required further experimental confirmation. The authors described the work as exploratory and preliminary, and it remains a single four-week rodent experiment with eight animals per arm, so it does not establish a comparative ranking that transfers to humans or to other tissues.
The study that tested both
- 01Animal in vivo2026
Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study
Biçer O, et al. · Jt Dis Relat Surg · rat Achilles tendon transection and repair; 32 male Sprague-Dawley rats in 4 groups of 8 (control, BPC-157, TB-500, combination), intraperitoneal administration for 4 weeks, with biomechanical, histopathological, histochemical and immunohistochemical analysis
Both peptides were associated with improved histopathological scores and extracellular matrix organisation at four weeks. Maximum load to failure was higher in both treated groups than in controls but reached statistical significance only for TB-500 (p < 0.05), which also showed significantly lower total Bonar (p = 0.016) and Movin (p = 0.017) scores. Collagen type I expression did not differ significantly between groups on immunohistochemistry, while collagen type III expression did. Combined treatment did not confer additional benefit compared with either agent alone.
Side by side.
| BPC-157 | TB-500 | |
|---|---|---|
| Evidence maturity | Preclinical only | Early clinical |
| Studies cited here | 15 | 15 |
| Published 2023 or later | 8 | 8 |
| Newest paper | 2026 | 2026 |
| Molecular class | Synthetic 15-amino-acid peptide whose sequence corresponds to a fragment of a protein found in gastric juice; it has no confirmed endogenous circulating counterpart. | Synthetic seven-residue fragment, Ac-LKKTETQ, marketed as an analogue of thymosin beta-4, a 43-amino-acid peptide that is genuinely endogenous and widely expressed. |
| Proposed mechanism | Preclinical work attributes effects to angiogenesis associated with VEGFR2 activation and upregulation, and to modulation of the nitric oxide system, with additional cytoprotective and gut-barrier effects reported in rodents. | Full-length thymosin beta-4 sequesters G-actin and promotes cell migration; published biology also covers endothelial migration and angiogenesis, epicardial activation in cardiac repair, anti-fibrotic activity and inflammation resolution. |
| Identity of the marketed molecule | Published rodent studies used the same pentadecapeptide that is sold, so the literature and the product describe one molecule. | Almost all published biology concerns full-length thymosin beta-4 rather than the Ac-LKKTETQ fragment. The fragment has very little independent pharmacology of its own, and its equivalence to the full-length peptide is assumed rather than demonstrated. |
| Strongest evidence tier | A 2025 systematic review in an orthopaedic sports medicine journal, synthesising a preclinical corpus; the human reports are uncontrolled. | Randomised, double-blind, placebo-controlled human trials, including phase 1 single- and multiple-dose studies and a phase 2 dry eye trial, all conducted with thymosin beta-4. |
| Human data | Two uncontrolled open-label pilot studies and one retrospective chart review, all originating from the same private clinic, plus one ex vivo study on surgically discarded human arterial tissue. No randomised controlled trial has been completed for any indication. | Completed randomised trials in healthy volunteers, severe dry eye, chronic venous ulcers, and a 2025 report covering both mice and patients with ST-segment elevation myocardial infarction. None of these trials addressed tendon, ligament or muscle injury. |
| Best-studied model | Rat transection and defect models: quadriceps muscle transection, medial collateral ligament transection, myotendinous junction detachment, and gastrointestinal and ischaemia-reperfusion injury. | Murine and zebrafish cardiac injury, rodent dermal and corneal wound healing, bleomycin-induced pulmonary fibrosis, experimental colitis and sepsis-associated kidney injury. |
| Regulatory and anti-doping status | No approved formulation in any jurisdiction; prohibited in professional sport, and 2025-2026 orthopaedic reviews characterised the human evidence as insufficient. | No approved product for musculoskeletal recovery; thymosin beta-4 is prohibited in sport and in equine competition, and several recent publications are doping-detection methods rather than efficacy studies. |
And what it does not.
The one direct comparison that exists is a four-week rat Achilles tendon experiment with eight animals per arm. In that study TB-500 was the only arm to reach statistical significance on maximum load to failure, and combining the two peptides added nothing over either alone. Those results describe one tissue, one species, one time point and one set of administration conditions, and the authors themselves labelled the work exploratory and preliminary. Away from that experiment the two evidence bases are not comparable in kind: BPC-157 rests on a large rodent corpus concentrated in a small number of closely affiliated research groups with no completed randomised human trial, while thymosin beta-4 has completed randomised human trials but none in the musculoskeletal indications for which TB-500 is marketed, and the specific fragment sold as TB-500 has almost no pharmacology of its own. Neither compound has controlled human evidence for tendon, ligament or muscle injury, which is the use that prompts the comparison in the first place.
Common questions.
- Which of the two peptides has been tested in a randomised, placebo-controlled human trial?
Thymosin beta-4 has: randomised, double-blind, placebo-controlled studies have been completed in healthy volunteers, in severe dry eye and in chronic venous ulcers. BPC-157 has no completed randomised controlled trial for any indication; its human record consists of two uncontrolled open-label pilot studies and one retrospective chart review, all from a single private clinic. None of the thymosin beta-4 trials examined tendon, ligament or muscle injury, so the trial record does not cover the marketed use for either compound.
- Did the rat Achilles tendon study find that the combination outperformed the single peptides?
It did not. The combination group showed significantly lower total Movin scores than untreated controls, but the authors reported that combined treatment conferred no additional benefit compared with either agent alone. They offered convergence on shared downstream pathways as a possible explanation and noted that this hypothesis required further experimental confirmation.
- Why does most TB-500 research describe thymosin beta-4 rather than TB-500 itself?
TB-500 is the synthetic Ac-LKKTETQ fragment, whereas the actin-binding region it derives from sits within a 43-amino-acid endogenous peptide. Nearly all published cardiac, corneal, dermal and anti-fibrotic biology was generated with the full-length peptide or its recombinant form. The two are frequently conflated, and the assumption that the short fragment reproduces full-length activity has not been demonstrated in published work.
- Are the two evidence bases comparable in quality?
They are not comparable in the same direction. BPC-157 has a much larger volume of animal work directly targeting tendon, ligament and muscle injury, but no controlled human data and limited independent replication. Thymosin beta-4 has stronger study designs in humans, including phase 1 and phase 2 randomised trials, but those trials addressed unrelated indications, and the fragment marketed as TB-500 was not the molecule tested.
- Has anything compared the two peptides in a tissue other than tendon?
No. The 2026 rat Achilles tendon study is the only located experiment in which both compounds were administered within one design. Every other publication that names both peptides is a narrative or scoping review of unapproved peptides in sports medicine, or an anti-doping analytical method, neither of which generates comparative efficacy data.
For research purposes only. Not for human consumption, diagnosis, treatment, or prevention of any condition. Nothing on this page is medical advice, and no comparison here should be read as a recommendation of either compound.